Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05924815 |
Recruitment Status :
Completed
First Posted : June 29, 2023
Last Update Posted : December 19, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy Participants | Drug: Aficamten Drug: Aficamten-matching Placebo Drug: Moxifloxacin | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 44 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Basic Science |
Official Title: | A Randomized, 2-Part, Single-Dose, Crossover Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval in Healthy Participants |
Actual Study Start Date : | May 15, 2023 |
Actual Primary Completion Date : | November 14, 2023 |
Actual Study Completion Date : | November 14, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Part A (Dose Finding Cohort 1): Aficamten 50 mg
Participants in this arm will receive a single oral dose of 50 mg aficamten.
|
Drug: Aficamten
Oral Tablet |
Experimental: Part A (Dose Finding Cohort 2): Aficamten 75 mg
Participants in this arm will receive a single oral dose up to 75 mg aficamten.
|
Drug: Aficamten
Oral Tablet |
Experimental: Part A (Dose Finding Cohort 3): Aficamten 100 mg
Participants in this arm will receive a single oral dose up to 100 mg aficamten.
|
Drug: Aficamten
Oral Tablet |
Experimental: Part B (TQT Study): Aficamten
Participants will receive a single oral dose of aficamten. The dose will be determined based on review of Part A PK parameters, echocardiogram parameters, safety, and tolerability for aficamten.
|
Drug: Aficamten
Oral Tablet |
Placebo Comparator: Part B (TQT Study): Aficamten-matching Placebo
Participants in this arm will receive a single oral dose of aficamten-matching placebo.
|
Drug: Aficamten-matching Placebo
Oral Tablet |
Active Comparator: Part B (TQT Study): Moxifloxacin 400 mg
Participants will receive a single oral dose of 400 mg moxifloxacin
|
Drug: Moxifloxacin
Oral Tablet |
- Part A: To determine the dose for Part B [ Time Frame: Baseline to End of Study, up to 8 weeks ]To determine the dose for Part B based on Part A PK and safety data.
- Part B: placebo-corrected dQTcF for aficamten [ Time Frame: Baseline to End of Study, up to 14.5 weeks ]To evaluate the effect of a single oral dose of aficamten on the QTc interval in healthy participants.
- Part B: placebo-corrected dQTcF for moxifloxacin [ Time Frame: Baseline to End of Study, up to 14.5 weeks ]To demonstrate assay sensitivity of the study to detect a small QTc effect using moxifloxacin as a positive control in healthy participants.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy, adult, male or female, 18-45 years of age, inclusive, at the screening visit.
- Continuous non-smoker who has not used nicotine- and tobacco -containing products for at least 3 months prior to the first dosing based on participant self- reporting.
- Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2 at the screening visit.
-
Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, and vital signs, as deemed by the PI or designee, including the following:
- Supine blood pressure is ≥ 90/40 mmHg and ≤ 140/90 mmHg at the screening visit.
- Oxygen saturation (SpO2) is ≥ 95% at the screening visit.
- Liver function tests (e.g., bilirubin, aspartate aminotransferase [AST], alanine aminotransferase [ALT]) considered not clinically significant in the opinion of the PI or designee at the screening visit.
- Estimated creatinine clearance ≥ 90 mL/min at the screening visit.
-
No clinically significant history and presence of ECG findings as judged by the PI or designee at the screening visit and first check-in, including each of the following:
- HR between 50 bpm and 100 bpm, inclusive.
- QTcF interval is ≤450 msec (males) and ≤460 msec (females).
- QRS ≤110 msec; if >110 msec, result will be confirmed by a manual over read.
- PR ≤220 msec.
- LVEF ≥65% at the screening visit.
Exclusion Criteria:
- History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
- History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05924815
United States, Arizona | |
Celerion, Inc 2420 | |
Tempe, Arizona, United States, 85283 |
Study Director: | Cytokinetics, MD | Cytokinetics |
Responsible Party: | Cytokinetics |
ClinicalTrials.gov Identifier: | NCT05924815 |
Other Study ID Numbers: |
CY 6019 |
First Posted: | June 29, 2023 Key Record Dates |
Last Update Posted: | December 19, 2023 |
Last Verified: | December 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
CK-3773274 CK-274 Aficamten |
Moxifloxacin Anti-Bacterial Agents Anti-Infective Agents Topoisomerase II Inhibitors |
Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |